News and Events >

BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results

BioMimetic's Augment Bone Graft Receives Positive Recommendation from FDA Advisory Committee

BioMimetic Therapeutics Receives Augment Bone Graft PMA Response Letter from FDA

BioMimetic Releases Data from its Augment Rotator Cuff Clinical Trial

BioMimetic Introduces Augmatrix Biocomposite Bone Graft

Newly Published rhPDGF-BB Pilot Data in Foot & Ankle International

Newly Published Augment Bone Graft Products Compare Favorably With Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion

What do you mean by Reject Ordinary?

Reject ordinary is a state of mind and call to action. This is not about us, as much as it is about the surgeon, our customer. Every surgeon is extraordinary—gifted with the ability to treat injuries, correct deformities and address the challenges of aging. We, too, embrace this call to excellence and choose to develop products that are innovative, backed by rigorous science and represented by people who are knowledgeable about the products they sell.

Read more about our advances here, so you too, can reject ordinary.



 


RECENT ANNOUNCEMENTS


BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results
May 9 2012

BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results
March 13 2012

BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
February 8 2012